Quelques intervenants participants au colloque ATHS 2021 :
Tarik Asselah (Clichy)
Tarik Asselah is a Full Professor of Medicine and Hepatology at Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, France.
Tarik Asselah is the Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation). He is MD and also holds a PhD in virology. His fields of research include chronic liver diseases, translational medicine and treatment of HBV, HCV and HDV infections with new direct-acting antivirals, for which he has been involved as a coordinator/principal investigator in several clinical trials. He coordinated major international clinical trials on HCV Genotype 4 infection, HBV and HDV. He has published more than 250 articles in the field of chronic liver diseases in major journals (NEJM, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, etc…). (H-index = 60). He has been selected as a rising star in Gastroenteology in 2009 by the United European Gastroenterology (UEG) in appreciation of his outstanding scientific work. He received awards for his genomic studies on HCV in 2005 from the French Association for the Liver Disease (AFEF), and for his leadership in Hepatology in 2019 from the Czech Hepatology Society.
Marc Auriacombe (Bordeaux)
Marc Auriacombe is a Professor of Psychiatry and Addiction medicine at the Medical School of the University of Bordeaux, Bordeaux, France and an Adjunct Associate Professor of Psychiatry at the University of Pennsylvania, Philadelphia, PA., USA. He is the director of the addiction research team at CNRS USR 3413 Sanpsy and medical director of the Addiction Treatment Services of the Charles Perrens Hospital in Bordeaux, France. He is the principal senior investigator of an integrated addiction research program funded by French national and
European funds. With Jean-Pierre Daulouède and Jean Tignol he has contributed to introduce the Addiction Severity Index in France in 1989. Marc Auriacombe was awarded the EUROPAD Award 2002 « Chimera d’Argento » « Dedicated to all those who dream of a better
world for drug addicts » and has published over 200 papers in research and educational journals and books in English, French and Spanish.
Nicolas Authier (Clermont-Ferrand)
Inserm 1107, Université Clermont Auvergne, CHU Clermont-Ferrand. Nicolas Authier est professeur des universités et praticien hospitalier, chef du Service de Pharmacologie Médicale et du Centre d’Evaluation et de Traitement de la Douleur du CHU de Clermont-Ferrand. Médecin psychiatre de formation spécialisé en pharmacologie et addictologie, il s’occupe notamment d’une consultation de pharmacodépendance. Ses travaux de recherche, au sein de l’UMR INSERM 1107 NEURO-DOL, se focalisent sur l’optimisation du bénéfice-risque des antalgiques dont le mésusage des médicaments opioïdes chez les patients douloureux et les patients dépendants ainsi que sur les stratégies de sevrage en opioïdes. En 2017, il créé l’Observatoire Français des Médicaments Antalgiques (OFMA). Il préside, depuis septembre 2018, les comités scientifiques successifs de l’ANSM sur l’expérimentation française d’accès au cannabis à usage médical. Il préside aussi le groupe de travail de la HAS pour l’élaboration de recommandations sur le bon usage des opioïdes et la prévention des surdoses.
Amine Benyamina (Villejuif)
Amine Benyamina est Psychiatre Addictologue à l’Hôpital Universitaire Paul Brousse à Villejuif, il est également Professeur des Universités à la Faculté de Médecine Paris XI.Il est responsable de plusieurs Diplômes Universitaires nationaux et internationaux.
Il est responsable du Centre de Recherche et de Traitement des Addictions. Il est Président de la Fédération Française d’Addictologie (FFA). Il est Président de l’Association Franco-Maghrébine de Psychiatrie. Il est rédacteur en chef de la revue Alcoologie et Addictologie et administrateur de la Société Française d’Alcoologie (SFA), de l’Association Française de Psychiatrie Biologique et Neuropsychopharmacologie (AFPBN). Il est l’auteur d’une cinquantaine d’articles scientifiques référencés traitants des questions de thérapeutique, de biomarqueurs et de comorbidités
psychiatriques et addictives. Il est également l’auteur de nombreux ouvrages à vocation académique et pédagogique et a coordonné plusieurs ouvrages collectifs. Il est également l’auteur d’ouvrages plus grand public traitant des questions d’addiction notamment le cannabis et l’alcool. Il est le fondateur du congrès de l’Albatros, un congrès international d’addictologie qui se tient tous les ans à Paris.
Christophe BERLIOCCHI (Biarritz)
Après avoir grandi entre Nice et Marseille et effectué ses études de droit à Aix-en-Provence, Christophe Berliocchi est journaliste à Sud Ouest, au Pays basque. Il a écrit La Guerre des clans à Marseille, à paraître aux éditions du Rocher en début d’année 2022. Le livre est le récit, sur 50 ans, depuis la French connection jusqu’au narcotrafic qui ronge les cités de Marseille depuis vingt ans, d’une lutte à mort, une lutte de pouvoir où les cadavres se ramassent à la pelle et ne se comptent plus, où l’argent coule à flot, pour accéder et s’installer durablement sur le trône de « Roi du crime organisé ». Christophe Berliocchi est également auteur, pour Atlantica, et éditeur.
Nicolas Bonnet (Paris)
Nicolas Bonnet est docteur en pharmacie, titulaire du master en santé publique de Paris X, j’exerce depuis 1999 dans le domaine de l’addictologie où j’ai pu développer des compétences spécifiques dans la clinique des addictions en milieux institutionnel, associatif, hospitalier et universitaire. Mon parcours professionnel en addictologie m’a permis d’acquérir des compétences dans 3 domaines principaux : la pharmacologie, la veille sanitaire et la pharmacie clinique. J’ai ainsi notamment travaillé à Médecins du Monde comme coordinateur national de la mission analyse des drogues XBT dont les travaux ont amené à la diffusion de la technique d’analyse par chromatographie couche mince, à Apothicom pour la création du Sterifilt ou bien à l’Observatoire français des drogues et toxicomanies au sein du pôle TREND. Je suis actuellement directeur du RESPADD, Réseau des établissements de santé pour la prévention des addictions et responsable de la consultation jeunes consommateurs de l’hôpital Pitié-Salpêtrière à Paris. Le RESPADD constitue le plus important réseau d’établissements de santé en Europe soit plus de 800 établissements de santé adhérents mobilisés et actifs dans la prévention et la prise en charge des conduites addictives. Il est à l’origine de la stratégie « Lieu de santé sans tabac » et du réseau « Lieu de santé promoteur de santé ». Investi de longue date en réduction des risques dans le secteur associatif, j’assure actuellement la présidence du CAARUD Proses à Montreuil. Enfin, après avoir été secrétaire général de l’Association française pour la réduction des risques je siège aujourd’hui au bureau du collectif Galilée.
Sandra Comer (New York)
Sandra D. Comer, Ph.D. Comer is Professor of Neurobiology in the Department of Psychiatry at Columbia University. She received her BS at Vanderbilt University and PhD at the University of Michigan for her research on the effects of abused drugs using preclinical models. Dr. Comer’s current research focus is on the clinical testing of medications for treating opioid use disorder, methods to maximize the use of naloxone by opioid users, and evaluations of the comparative abuse liability of prescribed pain medications. Dr. Comer recently served as President of the College on Problems of Drug Dependence, the longest standing scholarly society in the U.S. devoted to research on substance use disorders, and currently is the Public Policy Officer for CPDD. Dr. Comer recently joined the Expert Advisory Panel on Drug Dependence for the WHO and has over 140 publications on substance use disorders.
Maurice Dematteis (Grenoble)
Neurologue de formation, Professeur d’Addictologie et de Pharmacologie, fondateur et chef du Service Universitaire de Pharmaco-Addictologie au CHU Grenoble Alpes, il a contribué à développer et à structurer l’enseignement de l’Addictologie dans sa Faculté et son interrégion. Il a participé aux différents groupes de travail nationaux (alcool, analgésiques opioïdes, substitution opioïde, nouveaux produits de synthèse / nouvelles substances psychoactives), à la rédaction des recommandations dans les troubles de l’usage d’alcool et des opioïdes, et à différentes études muticentriques. De par sa formation, Maurice Dematteis s’intéresse particulièrement aux addictions médicamenteuses, à leur caractérisation et à leur prise en charge. Enfin, il a développé le programme ETAPE, programme novateur inspiré de l’éducation thérapeutique pour les entourages de consommateurs.
Don C Des Jarlais (New York)
Don C. Des Jarlais, Ph.D. is Director of Research for the Baron Edmond de Rothschild Chemical Dependency Institute at Beth Israel Medical Center, a Senior Research Fellow with the National Development and Research Institutes, Inc. and a Guest Investigator at Rockefeller University in New York. He began his research on AIDS in 1982. As a leader in the fields of AIDS and injecting drug use, Dr. Des Jarlais has published extensively on these topics including papers in the New England Journal of Medicine, the Journal of the American Medical Association, Science and Nature. He has been particularly active in international research, having collaborated on studies in twenty-five different countries. He serves as a consultant to various institutions, including the Centers for Disease Control and Prevention, the National Institute on Drug Abuse, the National Academy of Sciences and the World Health Organization. He is a former commissioner for the US National Commission on AIDS, and is currently a Core Group Member of the UNAIDS Reference Group on HIV and Injecting Drug Use. In 2010 Dr. Des Jarlais was elected to the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board (SAB).
Zoe Dubus (Aix-Marseille)
Zoë Dubus est doctorante en histoire contemporaine à l’Université d’Aix-Marseille sous la direction d’Anne Carol (AMU) et de Vincent Barras (IHM, Lausanne). Sa recherche traite des transformations des pratiques médicales ainsi que des politiques de santé en lien avec l’utilisation de psychotropes, du XIXe siècle à nos jours en France. Elle s’attache à comprendre les relations qu’entretiennent les médecins avec les produits modifiant la conscience et la sensibilité, conçus alternativement comme des médicaments innovants ou comme des toxiques, notamment le LSD, la morphine et la cocaïne. Elle est également membre du GeFeM, groupe de recherche universitaire sur le genre, et l’une des fondatrices de la Société psychédélique française. Sa présentation lors du colloque ATHS 2021 portera sur l’émergence des psychothérapies assistées au LSD (1950-1970).
Jason Farrell (Amsterdam)
Mr.Jason Farrell is a pioneer in designing and implementing integrated “one-stop-shop” care. For 30 years, he has successfully fought for access to health care, human rights and prevention services for drug users and people living with HIV, regardless of sexual orientation or gender.
He founded the Positive Health Project (PHP) in 1993, the first low threshold, multi-service, HIV prevention, needle syringe program with on-site medical program for drug users in the United States, based on the successful Dutch model: harm reduction. In 2009 Jason Farrell moved to the Netherlands and worked with Correlation European Harm Reduction Network, advising on national HCV action plans and implementing HCV testing and prevention interventions within EU harm reduction programs. Over the years, Jason has served by invitation as an expert member of advisory groups at the European Center for Disease Control, the European Monitoring Center for Drugs and Drug Addiction, and the European HIV/HCV Testing Week Working Group. Presently, Jason Farrell is the director of Stichting Choices Support Center in Amsterdam. Choices Support Center (Choices) is designed to provide multi-disciplinary treatment readiness services for individuals struggling with addiction and high-risk behaviours. Choices low threshold services support individuals at risk for HIV, HCV and STIs due to substance use in taking the first steps towards creating a suitable prevention plan or finding appropriate treatment. The core values of Choices are – compassion, collaboration, and empowerment.
Gabriele Fischer (Vienne)
University professor, Dr. Gabriele Fischer works as psychiatrist & neurologist and is head of the Addiction Clinic at Medical University of Vienna. She is involved in many epidemiological clinical and psychopharmacological studies in the field of substance use disorder and non – substance related addictions including the topic of co-morbidities. Pr Gabriele Fischer has over 150 peer- reviewed publications.
She is, inter alia, member of the European Monitoring Center for Drugs and Drug addiction (EMCDDA) and Member of General Medical Council in Austria.
Andrew Freedman (Denver)
Andrew Freedman brings vast experience from his three years as the State of Colorado’s first Director of Cannabis Coordination. During this time, he developed distinctive experience effectively implementing voter-mandated legalized adult-use and medical cannabis while protecting public health, maintaining public safety, and keeping cannabis out of the hands of children.
Andrew’s role in developing a successful operating model for cannabis regulation and stakeholder collaboration was identified as one of the reasons for the State of Colorado’s success in implementing adult-use cannabis legalization by the Brookings Institution. (Lire la suite)
Albert Garcia-Romeu (Baltimore)
Albert Garcia-Romeu, Ph.D. is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine. His research examines the effects of psychedelics in humans, with a focus on psilocybin as an aid in the treatment of addiction and other health conditions. He received his doctorate in Psychology in 2012 from the Institute of Transpersonal Psychology in Palo Alto, CA, where he studied self-transcendence and meditation, and their relationship to mental health. His current research interests include clinical applications of psychedelics, mindfulness, and altered states of consciousness and their underlying psychological mechanisms. He also studies real-world drug use and impacts on public health, and the role of spirituality in mental health and addiction. He is a founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research and the International Society for Research on Psychedelics.
Frank Gray (Londres)
Dr. Frank Gray completed his medical degree at the University of Pretoria and specialist training in pharmaceutical medicine through the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. His clinical practice before pharmaceutical medicine focused on emergency care, anaesthesia and intensive care. He has over 20 years of experience in pharmaceutical medicine spanning all phases of medicines development.
Margaret Haney (New York)
Dr. Margaret (Meg) Haney is a Professor of Neurobiology (in Psychiatry) at the Columbia University Irving Medical Center. As the Director of the Cannabis Research Laboratory and Co-Director of the Substance Use Research Center, Dr. Haney is internationally recognized for her expertise in cannabis and cannabinoids. Her current work focusses on (1) conducting placebo-controlled studies testing the efficacy of potential treatment medications for Cannabis Use Disorder, and (2) testing the potential therapeutic effects of cannabis and its constituents for a range of indications, including appetite-enhancement, experimental pain, chemotherapy-induced neuropathy, and Obsessive-Compulsive Disorder. Dr. Haney’s research has been continuously supported by the National Institute of Health since 1999. She has authored more than 140 articles in peer-reviewed journals, 11 book chapters, is an Associate Editor for Cannabis and Cannabinoid Research, is an Advisory Editor for Psychopharmacology, and recently co-edited Neuropsychopharmacology Reviews 2018, Cannabis and Cannabinoids: From Synapse to Society. Dr. Haney is a longstanding participant in NIH review groups, is a Fellow at the American College of Neuropsychopharmacology, and the recent past President of the College on Problems of Drug Dependence.
John Hudak (Washington)
John Hudak is a Senior Fellow in Governance Studies and Deputy Director of the Center for Effective Public Management at the Brookings Institution. His research examines questions of presidential power; intergovernmental relations; campaigns and elections; and international, federal, and state cannabis policy. He is the author of the book Marijuana: A Short History (2016; 2nd ed. 2020), which traces the policy and political history of cannabis in the United States. He holds undergraduate degrees in political science and economics from the University of Connecticut and a Masters degree and Ph.D. from Vanderbilt University.
Marie Jauffret-Roustide (Paris)
Marie Jauffret-Roustide is a Research Fellow, Sociologist at the French National Institute of Health and Medical Research (Inserm) in France, Paris. She is the leader of an international comparative research on the history of harm reduction between France and North America. She proposes to analyze three representative contemporary drug policy issues affecting and partially North America and Europe (France) : the history of opioid substitutive treatments, the opioid overdose crisis, and the controversy on drug consumption rooms. Marie Jauffret-Roustide’s research focuses on drug policy and harm reduction paradigm, ethnicity and gender issues, laws, and regulations, structural inequalities in health and social policies, and patient groups’ and users’ involvement in drug policy changes, including analyses of the biomedicalization process of addiction. (Lire la suite)
Matthew W. Johnson (Baltimore)
Matthew W. Johnson, Ph.D, is the Susan Hill Ward Professor of Psychedelics in the Department of Psychiatry & Behavioral Sciences at Johns Hopkins University School of Medicine. Working with psychedelics since 2004, he is one of the world’s most widely published experts on psychedelics. Matt published psychedelic safety guidelines in 2008, helping to resurrect human psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in cancer distress in 2016. His 2018 psilocybin review recommended Schedule IV upon potential medical approval. Matt also conducts behavioral economic research on the psychology of addiction and sexual risk. He is a past President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and current President of the International Society for Research on Psychedelics. He has been widely interviewed about drugs and addiction, including by 60 Minutes, New York Times, Washington Post, Wall Street Journal, BBC, CNN, Fox Business News, NPR, & Michael Pollan.
Karl Mann (Mannheim, Germany)
Prof. Emeritus and Senior professor, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, University of Heidelberg/Germany. Karl Mann was appointed the first chair in Addiction Research in Germany in 1999 and held this position at the University of Heidelberg until he retired in 2014. From 2006 – 2014 he served as Deputy Director of the Central Institute of Mental Health, Mannheim. K.M. received his M.D. at the University of Mainz in 1977 and his PhD at the University of Tuebingen in 1990. He was a medical intern in Concord, NH in 1974 and 1975 and a Research fellow in Paris 1978-1979. He holds a Board Certification for Neurology, Psychiatry & Psychotherapy. His research concentrates on addiction mechanisms and randomized controlled treatment trials. His main research methods are psychopharmacology, structural and functional neuroimaging and genetics with a focus on alcoholism and gambling. This work and its policy implications were published in more than 500 peer reviewed papers and 20 books. From 2005 to 2009 he was ranked 3rd in the list of the most productive alcohol researchers worldwide*.
Icro Maremmani (Pise)
Icro Maremmani, MD graduated at the Medical School of the University of Pisa and specialized in Psychiatry cum laude at the University of Pisa. At present he is “Qualified full professor of Psychiatry” and Professor of Addiction Medicine at the University of Pisa, Italy. His expertise field is agonist opioid treatment of heroin addicts, especially patients with dual disorders. He is founding member and Past President of Italian Society of Addiction Medicine (SITD)and Founding member and President of the European Opiate Addiction Treatment Association – EUROPAD. He is Founding President of World Federation for the Treatment of Opioid Dependence (WFTOD), NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC), based in New York, NY, USA.He is founding member and general secretary of the World Association on Dual Disorders (WADD). He received Dole and Nyswander Award in 1994; Chimera Career Award in2004, SEPD Award in 2015, and ISAM fellowship award in 2016. He serves also as editor in chief of Heroin Addiction and Related Clinical Problems and academic editor of IJERPH and JCM.Up to present has published more than 600 scientific and professional papers and 20 books. Presently taking part, as active member, more than 450 scientific meetings.
Jan K MELICHAR (Cardiff)
Jan K MELICHAR , MD FRCPsych, est un psychiatre consultant en toxicomanie du NHS,
maître de conférences invité (psychopharmacologie, Université de Bath) et professeur invité (Université du Pays de Galles du Sud). Il est membre élu du Royal College of Psychiatrists et fait partie de l’exécutif national de la faculté des toxicomanies du Collège. Il fournit régulièrement des conseils au gouvernement, à l’industrie et aux commissaires. Il a précédemment travaillé en tant que directeur médical, fondé une start-up de dispositifs médicaux et mis en place une unité régionale de désintoxication. En 2020, dans le cadre des développements de Covid-19, il a présenté au gouvernement gallois une demande de financement de l’utilisation à l’échelle nationale de la seule injection mensuelle de remplacement des opioïdes à longue durée d’action autorisée au Royaume-Uni. En collaboration avec ses collègues, il a déployé ce programme dans tout le pays de Galles auprès de plus de 1000 patients et a personnellement administré plus de 400 injections à plus de 100 patients. Ses intérêts de recherche comprennent la recherche en laboratoire pour comprendre ce qui cause les avantages remarquables de la buprénorphine injectable à longue durée d’action et le développement de voies de désintoxication et de traumatisme correctement étudiées.
Fadi Meroueh (Villeneuve-Lès-Maguelonne)
Le Dr Fadi Meroueh est actuellement praticien hospitalier, addictologue et Chef de Service de l’Unité Sanitaire de la prison de Villeneuve-les-Maguelone, rattachée au CHU de Montpellier. En 2018, il a été élu président de Health Without Barriers (HWB), la Fédération européenne pour la santé en prison, qui représente les professionnels de la santé en prison, soutient les pratiques de soins de santé fondées sur des données probantes et défend les droits des personnes détenues à la santé. L’unité sanitaire a pour mission de fournir en prison des services de santé égaux à ceux fournis à l’extérieur. Une attention particulière est accordée aux addictions et à la gestion des maladies infectieuses (notamment l’Hepatite C) chez les personnes détenues. Auteur et chercheur, avec plusieurs articles évalués par des pairs à son actif, et 23 ans de travail sur des programmes de prévention et de traitement en milieu carcéral en Europe, en Afrique du Nord et en Afrique de l’Ouest, Fadi Meroueh est membre de nombreux groupes d’experts sur la santé en milieu carcéral, notamment des groupes convoqués par l’Organisation Mondiale de la Santé, l’OEDT, l’ECDC, l’UNODC… Le Dr Meroueh a également une activité hebdomadaire dans un CSAPA, « Arc-en-Ciel » à Montpellier..
Ivan Montoya (Bethesda)
Dr. Ivan Montoya is the Deputy Director of the Division of Pharmacotherapies and Medical Consequences (DPMC) and Senior Medical Officer at the National Institute on Drug Abuse (NIDA). He received a Doctor in Medicine degree from the University of Antioquia (Colombia) and a Masters in Public Health from The Johns Hopkins School of Public Health. He completed residency training in Psychiatry at the University of Antioquia and the Johns Hopkins University. He has been a Fulbright-Hubert H. Humphrey Fellow at The Johns Hopkins School of Public Health, Visiting Fellow at the Intramural Research Program of NIDA, Director of the Practice Research Network of the American Psychiatric Association, and consultant for the World Health Organization. He has published extensively in the areas of etiology, prevention, treatment (pharmacological and non-pharmacological), and medical consequences of drug abuse.
Mickael Naassila (Amiens)
Mickaël Naassila, Professor of physiologie at the University of Picardie Jules Verne (Amiens, France) and director of the INSERM UMR 1247 research unit (Research Group on Alcohol& Pharmacodependences – GRAP – https://grap.u-picardie.fr). President of the French Society of AlcohologySFA – https://www.sfalcoologie.asso.fr and vice-presidentof the French Federation of addictology FFA – http://www.addictologie.org – President of the 2019 meeting of the European Society on Biomedical Research on Alcoholism (ESBRA) ( https://www.esbra.com, Lille Grand Palais September 21-24th 2019 – http://esbra2019.org). Head of the Addictology University diploma of Amiens University (https://bit.ly/1Pnn9DH ). Partner of the european research project PsiAlc ANR ERA-NET Neuron 2019-2022 – https://www.psialc.org, Preclinical Phase II Testing of Psilocybin in Alcohol Addiction and Epigenetic and Neuroimaging Studies on the Mode of Action.
Milton Romani (Montevideo)
Embajador Milton Romani Gerner : Licenciado en Psicología. Docente de Psicopatología de la Universidad de la República Oriental del Uruguay. Secretario General de Junta Nacional de Drogas de la Presidencia de la República (2005-2011/2015-2016) Uruguay. Embajador Itinerante para Drogas y DDHH. Representante Permanente de Uruguay ante OEA (2012-2014). Representante de Uruguay en: Comisión de Estupefacientes de NNUU, Comisión Interamericana contra el Abuso de Drogas CICAD-OEA, Reunión Especializada de Autoridades de Aplicación en Materia de Drogas del MERCOSUR (RED), Consejo Suramericano para Problema Mundial de Drogas de UNASUR. Jefe de Delegación de Uruguay en la Sesión Especial de la Asamblea General de Naciones Unidas (UNGASS 2016)
Bernard P. Roques (Paris)
Bernard P. Roques learned degrees in pharmacology at Paris University and a PhD in physical chemistry at the EcolePolytechnique. Professor of Pharmacochemistry at Univ. Paris V and Director of an unit CNRS/INSERM (1976-2001). His research spans areas such as 1) DNA poly-intercalators; 2) metallopeptidase inhibitors active in pain treatment and cardiovascular domain with creation of start-up such as Pharmaleads and Quantum Genomics. He develop drugs such as Tiorfan and anti-diabetic Stagid both on the market. Two of the DENKIs, PL37 and PL265, are now in phase II clinical trials active on diabetic neuropathy. Bernard P. Roques is member of the French and European Academies of Sciences. He has received a great number of international awards and published more than 500 papers in international journals. He organised several international meetings.
Perrine Roux (Marseille)
Perrine Roux is a pharmacist and public health researcher with over twenty years of experience in the fields of HIV, Hepatitis C, addiction, and harm reduction. After a two-year post-doc at the Substance Use Research Center in Columbia University, she was awarded the position of permanent researcher at the French National Institute for Medical Research (INSERM) SESSTIM – Unit 1252 in Marseille, France. She is the PI of several mixed-method, multidisciplinary projects related to access to care and prevention for people who use drugs. Perrine currently leads a research group in the SESSTIM unit on community-based research on HIV and harm reduction, and has over eighty publications in this field.
.
Fuschia Serre (Bordeaux)
Fuschia Serre graduated with a Master degree in Neurosciences and a PhD in Psychology from the University of Bordeaux, France. She is Research Engineer and clinical research coordinator at Addiction research team of Sanpsy CNRS USR 3413 at University of Bordeaux. Her research interests cover issues of assessments of addiction related behavior with a special interest in the Ecological Momentary Assessment (EMA) methods. Her research topic is related to predictors of relapse with a special focus on craving and its behavioral correlates in human models
.
Christian Sueur (Lyon)
Psychiatre, praticien hospitalier, chercheur depuis le début des années 1980 sur les questions liées aux usages des drogues, et en particulier, sur l’usage thérapeutiques des substances cannabinoides, et psychédéliques, en psychiatrie. Christian Sueur a travaillé au C.S.S.T. de l’Association Abbaye (1982), puis au Centre Saint Germain des Prés (1991), puis au Centre Méthadone de Médecins du Monde (1994), responsable durant les années 90 de l’Antenne Toxicomanie de la Maison d’Arrêt de Fleury Mérogis, (initiateur des Traitements de Substitutions aux Opiacés dans les prisons françaises (1991-2000)), co-fondateur des Missions Raves de Médecins Du Monde (1996-1999), membre du Comité scientifique de l’OFDT lors de la mise en place des systèmes TREND et SINTES (1998-1999) en faveur de l’analyse des drogues de synthèse (ecstasy…) et de la Réduction des Risques dans les Évènements Festifs Techno, Responsable de Mission de MDM en Tchétchénie (1995-1998), puis Praticien hospitalier en Guadeloupe (CHU Pointe à Pitre 2000-2006), puis Responsable du Service de Pédopsychiatrie du Centre Hospitalier de Tahiti (2007-2017). Depuis 2018, pédopsychiatre au Centre Hospitalier du Vinatier, à Lyon. Depuis 2018, a travaillé en pédopsychiatrie et en addictologie à Lyon, puis à Carcassonne.
Steffanie Strathdee (University of California San Diego)
Dr. Steffanie Strathdee is an infectious disease epidemiologist who is Associate Dean of Global Health Sciences and Harold Simon Professor of Medicine at the University of California San Diego). She has studied the syndemics of HIV, viral hepatitis, TB and STIs among substance users on the Mexico-US border for 15 years and has now extended this research to COVID-19. She and her husband recently co-authored a memoir, The Perfect Predator: A Scientist’s Race to Save Her Husband from a Deadly Superbug. Strathdee was named one of TIME magazine’s Most Influential People in Health Care in 2018.
Christian Trepo (Lyon)
Christian Trepo, MD, PhD graduated from the University of Lyon and was granted a fellowship by the Fogarty International Center National Institutes of Health to complete his training in Virology and in Hepatology at Cornell University in New-York.
He was then promoted Professor of Medicine and Gastroenterology at the Lyon Medical School, and Chief of the Liver Unit. He is presently Emeritus Professor at Croix-Rousse University Hospital and at Inserm Unit 1052 of Lyon Cancer Research Center (CRCL). Past-President of the French Association for the Study of the Liver, ChristianTREPO was awarded the Career Achievement Award from EASL (European Association for the Study of the Liver). His research and clinical interests are directed at hepatitis viruses associated diseases and their therapy.
Wim Van Den Brink (Amsterdam)
Wim Van Den Brink (1952) received his medical degree in 1981 from the Free University in Amsterdam. After his psychiatric residency in Groningen (1981-1986), he was a fellow at the Psychiatric Epidemiology Training program at Columbia University in New York. In 1989 he received his PhD degree form the State University of Groningen, the Netherlands. Since 1992 he is full professor of Psychiatry and Addiction at the Academic Medical Center of the University of Amsterdam. He is also the director of the Amsterdam Institute for Addiction Research (AIAR). In 2014 he received the life time achievement award for science from the Netherlands Association of Psychiatry and in 2015 he was granted the status of honorable (Lire la suite)